期刊文献+

复方积雪草苷凝胶贴膏的制备工艺研究 被引量:5

Preparation Process of Compound Asiaticoside Gel Plasters
下载PDF
导出
摘要 目的:筛选复方积雪草苷凝胶贴膏的处方,确定最佳制备工艺。方法:采用正交设计法,以凝胶贴膏的初黏力、持黏力、综合外观为考察指标,对复方积雪草苷凝胶贴膏进行综合评分,考察不同基质辅料比例对复方积雪草苷凝胶贴膏的影响,优选最佳处方工艺。结果:最佳处方基质配比为甘羟铝:EDTA:甘油:CMC-Na=0.25:0.05:45:1。结论:按照最佳工艺条件制备的复方积雪草苷凝胶贴膏黏附力好,外观涂布均匀,能适应大生产的需要。 Objective: To optimize the formula of compound asiaticoside gel plasters, and determine the optimal preparation process. Methods:Using the initial adhesion, viscosity and appearance as the indices, the gel plasters were evaluated by orthogonal design in order to study the effects of various base ratios on the preparation and screen the optimal formula and preparation process. Re-sults:The optimal formula was dihydroxyaluminium aminoacetate∶EDTA∶glycerol∶CMC-Na of 0. 25∶0. 05∶45∶1. Conclusion: Com-pound asiaticoside gel plasters with the optimal formula and preparation technique show good adhesion and uniformity, which can meet the need of large-scale production.
出处 《中国药师》 CAS 2014年第10期1672-1674,共3页 China Pharmacist
基金 湖北省卫生厅课题(编号:JX6B27)
关键词 复方积雪草苷 凝胶贴膏 基质 制备工艺 Compound asiaticoside Gel plasters Matrix Preparation
  • 相关文献

参考文献8

二级参考文献17

  • 1申洪.免疫组织化学染色定量方法研究(Ⅲ)[J].中国组织化学与细胞化学杂志,1995,4(1):89-92. 被引量:398
  • 2李勇,何文,常聪,何杨虎,何平平.水性巴布剂基质配方研究[J].中国药师,2006,9(10):911-913. 被引量:20
  • 3Jeon GC,Park MS,Yoon BY.Antitumor Activity of Spinasterol Isolated from Pueraria Roots[J].Exp Moi Med,2005,37(2):111-120.
  • 4[4]Chin D,Boyle GM,Parsons PG,et al.What is transforming growth factor-beta (TGF-β)[J].J Plast Surg,2004,57,215-21.
  • 5[5]Shah M,Foreman DM,Ferguson MWJ,et al.Neutralisation of TGFβ1 and TGF-β2 or exogenous addition of TGF-b3 to cutaneous rat wounds reduces scarring[J].J Cell Sci,1995,108,985-1002.
  • 6[6]Soo C,Beanes SR,Hu FY,et al.Ontogenetic transition in fetal wound transforming growth factor-beta regulation correlates with collagen organization[ J].Am J Pathol,2003,163,2459-76.
  • 7[7]Sumiyoshi K,Nakao A,Setoguchi Y,et al.Smads regulate collagen gel contraction by human dermal fibroblasts [J].Br J Dermatol,2003,149,464-470.
  • 8[8]Yamane K,Suzuki H,Ihn H,et al.Cell type-specific regulation of the TGF-beta-responsive alpha2 (Ⅰ) collagen gene by CpG methyla tion[J].J Cell Physiol,2005,202,822-30.
  • 9[9]Denis LJ,Verweij J.Matrix metalloproteinase inhibitors:present achievements and future prospects[J].Invest New Drugs,1997,15,175-85.
  • 10日本公定书协会.第十二改正日本药局方解说书[M].东京:广川书店,1991.A136-141.

共引文献262

同被引文献84

引证文献5

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部